These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2530797

  • 1. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K.
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract] [Full Text] [Related]

  • 2. A pharmacokinetic dose titration study in adult and elderly depressed patients.
    Hebenstreit GF, Fellerer K, Zöchling R, Zentz A, Dunbar GC.
    Acta Psychiatr Scand Suppl; 1989; 350():81-4. PubMed ID: 2530795
    [No Abstract] [Full Text] [Related]

  • 3. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements.
    Nielsen OA, Morsing I, Petersen JS, Larsen T, Møller SE, Manniche PM, Skausig OB.
    Acta Psychiatr Scand; 1991 Sep; 84(3):233-41. PubMed ID: 1835251
    [Abstract] [Full Text] [Related]

  • 4. Paroxetine plasma levels: lack of correlation with efficacy or adverse events.
    Tasker TC, Kaye CM, Zussman BD, Link CG.
    Acta Psychiatr Scand Suppl; 1989 Sep; 350():152-5. PubMed ID: 2530776
    [No Abstract] [Full Text] [Related]

  • 5. Paroxetine: pharmacokinetic and antidepressant effect in the elderly.
    Lundmark J, Scheel Thomsen I, Fjord-Larsen T, Manniche PM, Mengel H, Møller-Nielsen EM, Pauser H, Wålinder J.
    Acta Psychiatr Scand Suppl; 1989 Sep; 350():76-80. PubMed ID: 2530794
    [Abstract] [Full Text] [Related]

  • 6. The pharmacokinetics of paroxetine in the elderly.
    Bayer AJ, Roberts NA, Allen EA, Horan M, Routledge PA, Swift CG, Byrne MM, Clarkson A, Zussman BD.
    Acta Psychiatr Scand Suppl; 1989 Sep; 350():85-6. PubMed ID: 2530796
    [No Abstract] [Full Text] [Related]

  • 7. The pharmacokinetics of paroxetine in renal impairment.
    Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD.
    Acta Psychiatr Scand Suppl; 1989 Sep; 350():89-90. PubMed ID: 2530798
    [No Abstract] [Full Text] [Related]

  • 8. A review of the metabolism and pharmacokinetics of paroxetine in man.
    Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH.
    Acta Psychiatr Scand Suppl; 1989 Sep; 350():60-75. PubMed ID: 2530793
    [Abstract] [Full Text] [Related]

  • 9. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline.
    Kuhs H, Schlake HP, Rolf LH, Rudolf GA.
    Acta Psychiatr Scand; 1992 May; 85(5):364-9. PubMed ID: 1534961
    [Abstract] [Full Text] [Related]

  • 10. Ability of charcoal to prevent absorption of paroxetine.
    Greb WH, Buscher G, Dierdorf HD, von Schrader HW, Wolf D.
    Acta Psychiatr Scand Suppl; 1989 May; 350():156-7. PubMed ID: 2530777
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacokinetics of paroxetine in patients with liver cirrhosis.
    Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D.
    Acta Psychiatr Scand Suppl; 1989 May; 350():91-2. PubMed ID: 2530799
    [No Abstract] [Full Text] [Related]

  • 12. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.
    Greb WH, Buscher G, Dierdorf HD, Köster FE, Wolf D, Mellows G.
    Acta Psychiatr Scand Suppl; 1989 May; 350():95-8. PubMed ID: 2530801
    [No Abstract] [Full Text] [Related]

  • 13. Absorption of paroxetine under various dietary conditions and following antacid intake.
    Greb WH, Brett MA, Buscher G, Dierdorf HD, von Schrader HW, Wolf D, Mellows G, Zussman BD.
    Acta Psychiatr Scand Suppl; 1989 May; 350():99-101. PubMed ID: 2530802
    [No Abstract] [Full Text] [Related]

  • 14. The clinical pharmacology of paroxetine in healthy subjects.
    Raptopoulos P, McClelland GR, Jackson D.
    Acta Psychiatr Scand Suppl; 1989 May; 350():46-8. PubMed ID: 2530788
    [No Abstract] [Full Text] [Related]

  • 15. Regional distribution of serotonergic pre- and postsynaptic markers in human brain.
    Laruelle M, Maloteaux JM.
    Acta Psychiatr Scand Suppl; 1989 May; 350():56-9. PubMed ID: 2530792
    [No Abstract] [Full Text] [Related]

  • 16. Platelet 3H-paroxetine binding in depressed patients.
    D'haenen H, De Waele M, Leysen JE.
    Psychiatry Res; 1988 Oct; 26(1):11-7. PubMed ID: 2976947
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.
    Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG.
    Acta Psychiatr Scand Suppl; 1989 Oct; 350():102-6. PubMed ID: 2530759
    [No Abstract] [Full Text] [Related]

  • 18. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites.
    Haddock RE, Johnson AM, Langley PF, Nelson DR, Pope JA, Thomas DR, Woods FR.
    Acta Psychiatr Scand Suppl; 1989 Oct; 350():24-6. PubMed ID: 2530779
    [No Abstract] [Full Text] [Related]

  • 19. Platelet 5-HT transport in depressed patients under double-blind treatment with paroxetine versus amitriptyline.
    Schlake HP, Kuhs H, Rolf LH, Bosse T, Schuhknecht E, Rudolf GA, Brune GG.
    Acta Psychiatr Scand Suppl; 1989 Oct; 350():149-51. PubMed ID: 2530775
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.
    Hrdina PD.
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):10-8. PubMed ID: 1931931
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.